IRVINE, Calif., March 05, 2026--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech company targeting age-related diseases, today announced it has entered an exclusive licensing agreement with ...

IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech company targeting age-related diseases, today announced it has entered an exclusive licensing agreement with Toray to develop ...

Cholelithiasis, characterized by the presence of gallstones, is a common condition in the United States, with 80% of affected individuals having no symptoms. Symptomatic gallstone disease encompasses ...

Compared with the use of SGLT2 inhibitors, the use of GLP-1 receptor agonists and DPP-4 inhibitors was associated with a similar risk for acute pancreatitis (hazard ratio [HR], 1.01; 95% CI, 0.90-1.13 ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

Biliary hyperkinesia is an emerging functional gallbladder disorder characterized by elevated gallbladder ejection fraction and right upper quadrant pain in the absence of gallstones. This case study ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Tardive dyskinesia, or TD, is a drug-induced movement disorder that can occur in individuals taking certain medications that block dopamine receptors in the brain. Most commonly, cases of TD are ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) ...

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing ...